Oligonucleotide Therapeutics Sector Heats Up: Active Financing and Breakthroughs in Chronic Disease Treatment

　　【Pharmaceutical Network Market AnalysisIn recent years, small nucleic acid drugs have become a focal point in the biopharmaceutical field due to their advantages, and their broad market prospects have attracted close attention from both capital and enterprises. Industry insiders pointed out that the rise of small nucleic acid drugs is mainly attributed to their huge market potential. Data predictions show that from 2024 to 2029, the global market size for small nucleic acid drugs will surge from $5.2 billion to $20.6 billion. Meanwhile, the sector is rapidly expanding into the field of chronic disease treatment, opening up broader development opportunities.
 

The continuous expansion of market space has directly driven the vigorous development of financing activities in the small nucleic acid drug field. Companies in China have frequently reported good news in financing, becoming a vivid portrayal of the vitality of this track. For instance, Leaderna recently announced the completion of a 150 million yuan Series A round of financing led by Daoyuan Capital and co-led by Qishen Venture Capital. Investors such as Jiale Capital, Chengdu Science and Technology Investment Group, Sichuan Pilot R&D Co., Ltd., Xiamen High-Tech Investment, Zengrui Minghe, followed on the investment. Existing shareholders including Chengdu先导, Yinman Fund, Huaige Capital, Jun Tian Venture Capital, Cao Jiaming, Huabo Instrument, continued to invest. Rigerna also recently announced the completion of a Pre-A round of financing exceeding 200 million yuan led by Kangjun Capital. Delian Capital, Huatai Genscript Fund, Jinyifu Xin, Guohai Innovation Capital, Lenovo Ventures, and existing shareholder Yuanxi Haihe participated in this round of investment.
 

Data shows that Leaderna focuses on core technological innovation and new drug development related to oligonucleotides. Currently, the company has successfully built three core technology platforms for small nucleic acid drug research and development with independent intellectual property rights: NEATL (Novel Enhancement and Modification Technology for Nucleic Acid Delivery), LOCATED (Lipid-Conjugated Extrahepatic Delivery Technology), and DIRECT (Dual-Target Interference by Single Molecule Technology). Relying on its core technological advantages, the company has achieved significant expansion in delivery technologies from liver-targeting to extrahepatic tissues, making key breakthroughs in multiple critical technological directions.
 

Leaderna Therapeutics Ltd. has implemented a comprehensive product layout in major chronic disease areas such as metabolic diseases and cardiovascular and cerebrovascular diseases. It is continuously advancing the development of differentiated pipelines with the aim of developing promising small nucleic acid drugs. Leaderna stated that this round of financing will mainly be used to promote the clinical development of its core small nucleic acid product pipeline, accelerate the continuous optimization of key technology platforms such as extrahepatic delivery, and further expand preclinical product layouts and core team building.
 

Rigerna, with innovation as its core driver, focuses on深耕 (deep cultivation) in the fields of kidney disease and metabolic disorders, aiming to become a深耕者 (key player) and变革者 (transformer) in the small nucleic acid pharmaceuticals sector. Through strategic布局 (planning), its lead pipeline has entered Phase II clinical trials and is expected to become the first approved small nucleic acid drug for IgA nephropathy. Addressing unmet clinical needs in kidney and metabolic diseases, Rigerna is developing multiple pipelines, creating a multi-layered and梯度 (staged) pipeline matrix.
 

Relevant persons from Rigerna stated that the successful completion of this round of financing not only provides a solid financial foundation for the company's innovative development but also injects strong momentum into its future rapid growth. The company will adhere to its original aspirations and strategic positioning, fully advancing Rigerna into a new phase of development. Driven by innovation, it will continuously overcome extracellular liver delivery bottlenecks, develop proprietary technologies and pipelines, accelerate clinical translation and development processes, and achieve the commercialization of innovative small nucleic acid drugs as soon as possible to benefit patients worldwide.
 

In addition, in January this year, Anlong Biotechnology, which focuses on gene therapy and small nucleic acid drug research and development, announced that it had completed a nearly 100-million-yuan B+ round of financing. It is reported that the company focuses on the treatment of chronic diseases, metabolic diseases, and nervous system diseases. Currently, Anlong Biotechnology is accelerating the research and development process of multiple innovative drugs. Among them, the suprachoroidal injection gene therapy product for wet age-related macular degeneration has completed Phase II clinical trial enrollment.
 

Ribo Bio, a company focused on the development and commercialization of small interfering RNA drugs, was listed on the Main Board of the Hong Kong Stock Exchange in January this year, raising over 1.8 billion Hong Kong dollars. The proceeds will mainly be used to advance the global multicenter clinical research of the company's core products, support the preclinical and clinical stage development of the R&D pipeline, and iteratively upgrade the small nucleic acid delivery technology platform. It is reported that currently, the company has built a full-technology-chain R&D platform with independent intellectual property rights, and has laid out a rich and differentiated product pipeline around disease areas such as cardiovascular metabolism, liver, and kidney.
 

Currently, pharmaceutical companies in China have gained a significant position in the global arena through independent technological innovation and product portfolio strategies. The active financing market and strong capital support have further fueled the continuous growth of these enterprises. In the future, with ongoing technological advancements and the clinical implementation of new products, small nucleic acid drugs are expected to offer novel therapeutic options for patients. Companies in China will continue to strengthen their efforts, achieving greater breakthroughs in global biopharmaceutical competition.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.